Huub H van Rossum - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Huub H van Rossum's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Huub H van Rossum
Verified
Specialist, Clinical Laboratory News (ADLM)
Netherlands
Beats
Deaths
Content
Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study
By Huub H van Rossum, Deutsches Herzzentrum München, Technische Universität München| Clinical Chemistry Verified The harmonization status of most tumor markers (TMs) is unknown. We report a feasibility study performed to determine whether external quality assessment (EQA) programs can be used to obtain insights into the current harmonization status of the tumor markers α-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9.
By Huub H van Rossum, design Xavier Dohr| Archiproducts@ Van RossumKITALERectangular solid wood coffee tableRequest prices/quoteRequest cataloguesRequest BIM/CADRetailers listADD TO WISHLIST OR PROJECTSave
Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study
By Huub H van Rossum, Deutsches Herzzentrum München, Technische Universität München| Clinical Chemistry Verified The harmonization status of most tumor markers (TMs) is unknown. We report a feasibility study performed to determine whether external quality assessment (EQA) programs can be used to obtain insights into the current harmonization status of the tumor markers α-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9.
Company Info
Clinical Laboratory News (ADLM)